JP2016520199A - 過敏性腸症候群を診断するための経路特異的マーカー - Google Patents

過敏性腸症候群を診断するための経路特異的マーカー Download PDF

Info

Publication number
JP2016520199A
JP2016520199A JP2016514524A JP2016514524A JP2016520199A JP 2016520199 A JP2016520199 A JP 2016520199A JP 2016514524 A JP2016514524 A JP 2016514524A JP 2016514524 A JP2016514524 A JP 2016514524A JP 2016520199 A JP2016520199 A JP 2016520199A
Authority
JP
Japan
Prior art keywords
score
antibody
ibs
marker
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016514524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520199A5 (enExample
Inventor
ステファン ウェスティン，
ステファン ウェスティン，
ファビヨラ セルヴァラジ，
ファビヨラ セルヴァラジ，
フレッド プリンセン，
フレッド プリンセン，
シャラット シン，
シャラット シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2016520199A publication Critical patent/JP2016520199A/ja
Publication of JP2016520199A5 publication Critical patent/JP2016520199A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016514524A 2013-05-24 2014-05-22 過敏性腸症候群を診断するための経路特異的マーカー Pending JP2016520199A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827506P 2013-05-24 2013-05-24
US61/827,506 2013-05-24
PCT/IB2014/061636 WO2014188378A1 (en) 2013-05-24 2014-05-22 Pathway specific markers for diagnosing irritable bowel syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019104805A Division JP2019194600A (ja) 2013-05-24 2019-06-04 過敏性腸症候群を診断するための経路特異的マーカー

Publications (2)

Publication Number Publication Date
JP2016520199A true JP2016520199A (ja) 2016-07-11
JP2016520199A5 JP2016520199A5 (enExample) 2017-06-29

Family

ID=50884973

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016514524A Pending JP2016520199A (ja) 2013-05-24 2014-05-22 過敏性腸症候群を診断するための経路特異的マーカー
JP2016514523A Pending JP2016521683A (ja) 2013-05-24 2014-05-22 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2019075081A Pending JP2019151637A (ja) 2013-05-24 2019-04-10 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2019104805A Pending JP2019194600A (ja) 2013-05-24 2019-06-04 過敏性腸症候群を診断するための経路特異的マーカー

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016514523A Pending JP2016521683A (ja) 2013-05-24 2014-05-22 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2019075081A Pending JP2019151637A (ja) 2013-05-24 2019-04-10 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP2019104805A Pending JP2019194600A (ja) 2013-05-24 2019-06-04 過敏性腸症候群を診断するための経路特異的マーカー

Country Status (14)

Country Link
US (5) US9891235B2 (enExample)
EP (2) EP3004892B1 (enExample)
JP (4) JP2016520199A (enExample)
KR (2) KR20160010621A (enExample)
CN (2) CN105579852B (enExample)
AU (3) AU2014269961A1 (enExample)
BR (2) BR112015029320A8 (enExample)
CA (2) CA2912993A1 (enExample)
HK (1) HK1223361A1 (enExample)
IL (2) IL242597B (enExample)
MX (1) MX367046B (enExample)
RU (2) RU2015155552A (enExample)
SG (2) SG11201509371XA (enExample)
WO (2) WO2014188378A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130704B2 (en) 2013-06-21 2018-11-20 Ondek Pty Ltd Immunotherapy composition and use thereof
JP2021526684A (ja) * 2018-06-07 2021-10-07 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ Ｉｂｓ患者を層別化する方法

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2912993A1 (en) 2013-05-24 2014-11-27 Nestec S.A. Pathway specific markers for diagnosing irritable bowel syndrome
KR20170005058A (ko) * 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
TWI690536B (zh) 2014-11-19 2020-04-11 英商Ｎｚｐ英國有限公司 化合物（一）
CA2968338A1 (en) 2014-11-19 2016-05-26 Nestec S.A. Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
CN107108687B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
KR102546748B1 (ko) 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
CA2968310A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
WO2016088068A1 (en) * 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
CN105987995A (zh) * 2015-02-04 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒
CN105987996A (zh) * 2015-02-09 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106399344B (zh) * 2016-06-01 2021-01-01 上海领潮生物新材料有限公司 一种vin-cdtb融合蛋白的制备方法
WO2018011691A1 (en) * 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
CN106188191A (zh) * 2016-07-13 2016-12-07 西安电子科技大学 基于gsh响应的诊治一体化有机分子探针及其制备方法
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US10428370B2 (en) 2016-09-15 2019-10-01 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
KR20190047023A (ko) * 2016-09-15 2019-05-07 썬 제노믹스 인코포레이티드 샘플에서 1종 이상의 유형의 다양한 미생물 집단으로부터 핵산 분자를 추출하는 범용 방법
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
KR20190095931A (ko) 2016-12-14 2019-08-16 프로제너티, 인크. 섭취가능한 디바이스를 사용하여 방출된 il-12/il-23 저해제로의 위장관 질환의 치료
WO2018112245A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018112240A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
MX2019006867A (es) 2016-12-14 2020-01-13 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina.
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054947A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EP3750168B1 (en) * 2018-02-09 2025-11-19 Metabolomic Diagnostics Limited A system and method of generating a model to detect, or predict the risk of, an outcome
KR102699211B1 (ko) * 2018-03-19 2024-08-26 후지필름 가부시키가이샤 정신 질환의 판정 방법
EP3785033B1 (en) * 2018-04-24 2025-12-10 Universiteit Gent Intestinal biomarkers for intestinal health of poultry
JP7421504B2 (ja) 2018-06-01 2024-01-24 ビオラ・セラピューティクス・インコーポレイテッド 胃腸のマイクロバイオームの検出および操作のためのデバイスおよびシステム
CN110607335B (zh) * 2018-06-14 2021-08-03 中国科学院微生物研究所 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法
CN109324132A (zh) * 2018-10-31 2019-02-12 杭州佰辰医学检验所有限公司 高通量检测色氨酸及其代谢产物的试剂盒及其应用
US11488699B1 (en) 2018-12-09 2022-11-01 Cerner Innovation, Inc. Microbiota activity sensor and decision support tool
US11842795B1 (en) * 2018-12-17 2023-12-12 Cerner Innovation, Inc. Irritable bowel syndrome diagnostic sensor and decision support tool
FR3094492A1 (fr) * 2019-04-01 2020-10-02 Polyneuros Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique
WO2020201457A1 (en) * 2019-04-03 2020-10-08 4D Pharma Cork Limited Methods of diagnosing disease
WO2020213732A1 (ja) * 2019-04-18 2020-10-22 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) * 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
WO2020232262A1 (en) * 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
CN111351870A (zh) * 2019-12-03 2020-06-30 康美华大基因技术有限公司 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒
EP4085256B1 (en) 2020-01-27 2024-01-24 Immundiagnostik AG Test and in vitro diagnosis of irritable bowel syndrome
WO2021152586A1 (en) * 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114755313B (zh) * 2021-01-08 2024-08-30 复旦大学附属华山医院 包含尿液nad+代谢物的急性肾损伤标志物
CN115724779B (zh) * 2021-09-01 2024-03-29 四川大学 酰胺烷二硫化合物、其制备方法和用途
WO2023122320A1 (en) * 2021-12-24 2023-06-29 Kuleon Llc Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists
WO2023180899A1 (en) * 2022-03-21 2023-09-28 Swain Manish Kumar Device and method for detecting diarrhea
CN116381222A (zh) * 2023-03-23 2023-07-04 北京巴瑞医疗器械有限公司 一种血清素发光免疫检测方法及血清素检测试剂盒
CN116990498B (zh) * 2023-09-28 2024-08-09 山东大学齐鲁医院 血浆色氨酸代谢物在儿童偏头痛诊断中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
WO2008022177A2 (en) * 2006-08-15 2008-02-21 Prometheus Laboratories, Inc. Methods for diagnosing irritable bowel syndrome
WO2010151699A1 (en) * 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2011053831A1 (en) * 2009-10-30 2011-05-05 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP2013511988A (ja) * 2009-11-25 2013-04-11 ネステク ソシエテ アノニム 過敏性腸症候群診断用の新規なゲノムバイオマーカー
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
US20140141990A1 (en) * 2011-05-16 2014-05-22 Nestec S.A. Performance of a biomarker panel for irritable bowel syndrome
JP2015533213A (ja) * 2012-10-05 2015-11-19 ネステク ソシエテ アノニム Ｉｂｓの診断マーカーとしての微生物バイオームに対する抗体、ストレス因子及びマスト細胞マーカー

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
CN1423656A (zh) * 1999-12-15 2003-06-11 卡比斯特制药公司 作为抗菌剂的脂肽
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2005041896A2 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100094560A1 (en) 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8278057B2 (en) 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
BRPI1013560A2 (pt) 2009-04-14 2018-06-19 Prometheus Laboratories Inc métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatória
US20120171672A1 (en) 2009-04-14 2012-07-05 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
US8445215B1 (en) * 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
CA2912993A1 (en) 2013-05-24 2014-11-27 Nestec S.A. Pathway specific markers for diagnosing irritable bowel syndrome
EP3078744B1 (en) * 2013-12-04 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
WO2008022177A2 (en) * 2006-08-15 2008-02-21 Prometheus Laboratories, Inc. Methods for diagnosing irritable bowel syndrome
JP2010506144A (ja) * 2006-08-15 2010-02-25 プロメテウス ラボラトリーズ インコーポレイテッド 過敏性腸症候群診断方法
WO2010151699A1 (en) * 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP2012531593A (ja) * 2009-06-25 2012-12-10 ネステク ソシエテ アノニム 過敏性腸症候群の診断方法
WO2011053831A1 (en) * 2009-10-30 2011-05-05 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP2013509593A (ja) * 2009-10-30 2013-03-14 ネステク ソシエテ アノニム 過敏性腸症候群の診断方法
JP2013511988A (ja) * 2009-11-25 2013-04-11 ネステク ソシエテ アノニム 過敏性腸症候群診断用の新規なゲノムバイオマーカー
US20140141990A1 (en) * 2011-05-16 2014-05-22 Nestec S.A. Performance of a biomarker panel for irritable bowel syndrome
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
JP2015533213A (ja) * 2012-10-05 2015-11-19 ネステク ソシエテ アノニム Ｉｂｓの診断マーカーとしての微生物バイオームに対する抗体、ストレス因子及びマスト細胞マーカー

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130704B2 (en) 2013-06-21 2018-11-20 Ondek Pty Ltd Immunotherapy composition and use thereof
JP2021526684A (ja) * 2018-06-07 2021-10-07 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ Ｉｂｓ患者を層別化する方法

Also Published As

Publication number Publication date
HK1223416A1 (en) 2017-07-28
AU2014269960A1 (en) 2015-11-26
KR20160010621A (ko) 2016-01-27
IL242595B (en) 2019-01-31
CN105579852B (zh) 2017-12-01
SG11201509370UA (en) 2015-12-30
WO2014188377A3 (en) 2015-03-05
SG11201509371XA (en) 2015-12-30
US9891235B2 (en) 2018-02-13
CA2912993A1 (en) 2014-11-27
JP2019194600A (ja) 2019-11-07
AU2014269961A1 (en) 2015-11-26
US20160139148A1 (en) 2016-05-19
US20180321259A1 (en) 2018-11-08
WO2014188378A1 (en) 2014-11-27
CN105579852A (zh) 2016-05-11
JP2016521683A (ja) 2016-07-25
BR112015029320A2 (pt) 2017-07-25
US20170307637A1 (en) 2017-10-26
EP3004068A2 (en) 2016-04-13
US10338083B2 (en) 2019-07-02
BR112015029320A8 (pt) 2023-01-03
EP3004892B1 (en) 2018-10-10
HK1223361A1 (zh) 2017-07-28
JP2019151637A (ja) 2019-09-12
US20180136233A1 (en) 2018-05-17
RU2015155552A (ru) 2017-06-27
AU2018214104A1 (en) 2018-08-30
KR20160013163A (ko) 2016-02-03
EP3004892A1 (en) 2016-04-13
US20160130279A1 (en) 2016-05-12
US9739786B2 (en) 2017-08-22
RU2015155590A (ru) 2017-06-29
CN105392780A (zh) 2016-03-09
CA2913108A1 (en) 2014-11-27
US10036759B2 (en) 2018-07-31
AU2014269960B2 (en) 2018-05-10
MX367046B (es) 2019-08-02
BR112015029318A2 (pt) 2017-07-25
IL242597B (en) 2019-02-28
WO2014188377A2 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
US10338083B2 (en) Pathway specific markers for diagnosing irritable bowel syndrome
JP6087974B2 (ja) 過敏性腸症候群の診断方法
ES2536088T3 (es) Métodos para el diagnóstico del síndrome de intestino irritable
JP2013509593A (ja) 過敏性腸症候群の診断方法
JP6329553B2 (ja) Ｉｂｓの診断マーカーとしての微生物バイオームに対する抗体、ストレス因子及びマスト細胞マーカー
CN103069276A (zh) Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒
WO2012158831A1 (en) Performance of a biomarker panel for irritable bowel syndrome
JP6779200B2 (ja) 川崎病の診断及び治療
US20210349094A1 (en) Detection of autoreactive fecal immunoglobulin a (iga) for diagnosis of lupus
WO2016129631A1 (ja) 川崎病の検査方法およびキット
HK1223416B (en) Method for diagnosing irritable bowel syndrome
Ajamian Investigating Markers of Intestinal Barrier Dysfunction in Gastrointestinal Diseases
sgi Diagnostic et al. Inflammatory Bowel Disease Biomarker Testing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190205

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614